{"id":18082,"date":"2025-09-10T15:15:51","date_gmt":"2025-09-10T09:45:51","guid":{"rendered":"http:\/\/localhost\/current-affairs\/2025\/09\/10\/india-licenses-adfalcivax-indigenous-malaria-vaccine\/"},"modified":"2026-10-29T09:28:03","modified_gmt":"2026-10-29T09:28:03","slug":"india-licenses-adfalcivax-indigenous-malaria-vaccine","status":"publish","type":"post","link":"https:\/\/www.class24.study\/current-affairs\/india-licenses-adfalcivax-indigenous-malaria-vaccine\/","title":{"rendered":"Centre Grants Licenses to Five Firms for Indigenous Malaria Vaccine"},"content":{"rendered":"

The Indian Council of Medical Research (ICMR) granted non-exclusive licences to five Indian biotechnology and pharmaceutical companies in September 2025 to support the further development and commercialisation of <\/span>AdFalciVax<\/b>, an indigenous multi-stage malaria vaccine candidate. The initiative marks an important step in India’s efforts to strengthen domestic vaccine research and develop new approaches to malaria prevention.<\/span><\/p>\n

Developed by ICMR’s Regional Medical Research Centre in Bhubaneswar, AdFalciVax was validated through collaboration with the National Institute of Malaria Research (NIMR) and the National Institute of Immunology (NII). The vaccine is designed to target multiple stages of the malaria parasite, with the aim of preventing infection and reducing transmission.<\/span><\/p>\n

Importantly, granting technology licences does not mean that the vaccine has received final regulatory approval or is available for public use. Further research, development, and the necessary regulatory steps remain essential.<\/span><\/p>\n

What Is AdFalciVax?<\/b><\/h2>\n

AdFalciVax is an indigenous recombinant multi-stage vaccine candidate designed to target <\/span>Plasmodium falciparum<\/span><\/i>, the parasite responsible for the most severe form of malaria.<\/span><\/p>\n

Unlike approaches that target only one stage of the parasite’s life cycle, AdFalciVax combines components intended to address both infection in humans and the parasite’s transmission to mosquitoes.<\/span><\/p>\n

How Does AdFalciVax Work?<\/b><\/h3>\n

The vaccine candidate combines two major antigen components:<\/span><\/p>\n

    \n
  • PfCSP (Plasmodium falciparum circumsporozoite protein):<\/b> Targets the parasite at the pre-erythrocytic stage, before it establishes infection in the blood.<\/span><\/li>\n
  • Pfs230 and Pfs48\/45-derived components:<\/b> Target parasite stages involved in transmission from infected humans to mosquitoes.<\/span><\/li>\n<\/ul>\n

    By targeting more than one stage of the parasite’s development, AdFalciVax aims to provide a dual benefit: helping prevent infection and reducing onward transmission. Its effectiveness and safety for human use must be established through the appropriate research and clinical evaluation.<\/span><\/p>\n

    Five Companies Licensed to Develop AdFalciVax<\/b><\/h2>\n

    In September 2025, ICMR granted non-exclusive technology licences to five Indian companies. The arrangement allows multiple manufacturers to undertake further development and work towards commercialisation.<\/span><\/p>\n

    List of Licensed Companies<\/b><\/h3>\n

    The five companies are:<\/span><\/p>\n

      \n
    1. Indian Immunologicals Limited<\/span><\/li>\n
    2. Techinvention Lifecare Private Limited<\/span><\/li>\n
    3. Panacea Biotec Limited<\/span><\/li>\n
    4. Biological E Limited<\/span><\/li>\n
    5. Zydus Lifesciences<\/span><\/li>\n<\/ol>\n

      The licensing process followed an Expression of Interest issued by ICMR. The non-exclusive arrangement is intended to broaden manufacturing participation and support wider access if the vaccine successfully completes development and receives the required approvals.<\/span><\/p>\n

      Role of Technology Transfer<\/b><\/h3>\n

      Technology transfer enables research organisations to share technical knowledge and production processes with qualified manufacturers. In the case of AdFalciVax, this arrangement is intended to support further development, manufacturing preparation, and eventual commercialisation, subject to regulatory requirements.<\/span><\/p>\n

      Key Features of the Indigenous Malaria Vaccine<\/b><\/h2>\n

      AdFalciVax uses recombinant technology and a multi-stage antigen design. Its development reflects India’s efforts to build domestic research and manufacturing capabilities for infectious-disease prevention.<\/span><\/p>\n

      Potential for Affordable Production<\/b><\/h3>\n

      The vaccine candidate uses a production platform based on <\/span>Lactococcus lactis<\/span><\/i>. This approach may offer opportunities for scalable manufacturing, although the final cost and production capacity will depend on further development and manufacturing assessments.<\/span><\/p>\n

      Room-Temperature Stability<\/b><\/h3>\n

      Reported development data indicate that the vaccine formulation has potential for extended stability at room temperature. This could be valuable in areas where maintaining a continuous cold chain is difficult.<\/span><\/p>\n

      However, storage conditions for any vaccine intended for public use must follow the final validated product specifications and regulatory guidance.<\/span><\/p>\n

      Why Is the Malaria Vaccine Important for India?<\/b><\/h2>\n

      Malaria remains a public health concern in several parts of the world, including India. Preventing infection and interrupting transmission require a combination of public health measures, including mosquito control, diagnostic testing, timely treatment, surveillance, and suitable preventive interventions.<\/span><\/p>\n

      Supporting Malaria Prevention<\/b><\/h3>\n

      If AdFalciVax demonstrates adequate safety and efficacy, it could eventually complement existing malaria-control measures. A vaccine designed to address both human infection and parasite transmission may offer an additional tool for public health programmes.<\/span><\/p>\n

      Strengthening Indigenous Vaccine Research<\/b><\/h3>\n

      The project highlights collaboration between public research institutions and Indian manufacturers. Such partnerships can help translate scientific research into potential health products, strengthen domestic biotechnology expertise, and build long-term capacity for vaccine development.<\/span><\/p>\n

      Current Development Status and Future Prospects<\/b><\/h2>\n

      The licences granted in 2025 represent a step towards further development and potential commercialisation, rather than confirmation of a completed vaccine rollout.<\/span><\/p>\n

      Before AdFalciVax can be used routinely in humans, its safety, immune response, and protective efficacy must be established through the relevant clinical and regulatory processes. Manufacturing quality, consistent production, and appropriate storage conditions will also need to be assessed.<\/span><\/p>\n

      The timeline for availability therefore depends on the progress of development and the required approvals.<\/span><\/p>\n

      Conclusion<\/b><\/h2>\n

      AdFalciVax is an indigenous multi-stage malaria vaccine candidate developed by ICMR with scientific collaboration from specialised research institutions. The licensing of its technology to five Indian companies in September 2025 represents progress towards further development and potential commercialisation. Its multi-stage design and possible storage advantages make it a promising research initiative, but its ultimate public health value will depend on clinical evidence, regulatory approval, and successful implementation.<\/span><\/p>\n

      Frequently Asked Questions<\/b><\/h2>\n